COCP
Cocrystal Pharma, Inc.
Next earnings Aug 12, 2026 · consensus $-0.17 EPS
Last earnings +1.0% on 2026-03-31
$1.02
▲ +0.99%$1.02▼ -31.54%
over 1Y
L $0.86EODHDH $1.94
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.0%
1W+2.0%
1M-8.9%
3M-1.0%
YTD+3.0%
1Y-31.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.53x); but revenue fell -69.3% YoY.
Cocrystal Pharma, Inc. shows $2.01M in FY2020 revenue (-69.3% YoY), a -438.5% net margin, and -139.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$14.2M | -$38.8M | -$18.6M | -$17.9M | -$9.02M |
| Net income | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.83M |
| Diluted EPS | — | -$4.77 | -$1.87 | -$1.72 | -$0.78 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$57.2M
EV / EBITDA—
EV / Sales28.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-62.8%
FCF yield-58.3%
Quality & risk
ROIC (est.)-12.6%
Free cash flow-$8.20M
Total debt$50.1M
Net cash-$43.1M
Altman Z-Score-48.97 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+35.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-09
- 8-K Reg FD disclosure2026-06-03
- DEF 14A Proxy statement2026-05-27
- 8-K Reg FD disclosure2026-05-26
- 10-Q Quarterly report2026-05-15
- 8-K Reg FD disclosure2026-04-30
- S-3 Shelf registration (potential raise)2026-04-23
- 8-K Reg FD disclosure2026-04-02
- 8-K Earnings results2026-03-31
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-032026-06-09open ↗4Period ending 2026-06-032026-06-03open ↗3Period ending 2026-06-032026-06-03open ↗8-KPeriod ending 2026-06-032026-06-03open ↗DEFA14AFiling2026-05-27open ↗DEF 14APeriod ending 2026-05-272026-05-27open ↗8-KPeriod ending 2026-05-262026-05-26open ↗10-QPeriod ending 2026-03-312026-05-15open ↗EFFECTFiling2026-05-01open ↗8-KPeriod ending 2026-04-302026-04-30open ↗CORRESPFiling2026-04-29open ↗UPLOADFiling2026-04-28open ↗
Frequently asked
- Is Cocrystal Pharma, Inc. (COCP) a buy?
- COCP currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.53x); but revenue fell -69.3% YoY.
- What is Cocrystal Pharma, Inc.'s quality score?
- COCP scores 47.745098039215684/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001412486, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 11:37:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.